Erlotinib is not effective in patients with JAK2V617F-positive polycythemia vera

Ann Hematol. 2015 Apr;94(4):717-9. doi: 10.1007/s00277-014-2247-1. Epub 2014 Nov 9.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Amino Acid Substitution
  • Antineoplastic Agents / therapeutic use*
  • Drug-Related Side Effects and Adverse Reactions / epidemiology
  • Erlotinib Hydrochloride
  • Female
  • Humans
  • Janus Kinase 2 / genetics*
  • Male
  • Middle Aged
  • Phenylalanine / genetics
  • Polycythemia Vera / drug therapy*
  • Polycythemia Vera / epidemiology
  • Polycythemia Vera / genetics*
  • Quinazolines / therapeutic use*
  • Treatment Outcome
  • Valine / genetics

Substances

  • Antineoplastic Agents
  • Quinazolines
  • Phenylalanine
  • Erlotinib Hydrochloride
  • JAK2 protein, human
  • Janus Kinase 2
  • Valine